Trade

Aarti Drugs share price

Balanced risk
  • 35%Low risk
  • 35%Moderate risk
  • 35%Balanced risk
  • 35%High risk
  • 35%Extreme risk
  • ₹375.20(0.27%)
    February 6, 2026 15:40:57 PM IST
    • NSE
    • BSE
  • Vol : 108.14 K (NSE + BSE)
    Last 20 day avg : 168.07 K

Aarti Drugs is trading 0.27% upper at Rs 375.20 as compared to its last closing price. Aarti Drugs has been trading in the price range of 377.85 & 371.20. Aarti Drugs has given -8.93% in this year & -1.61% in the last 5 days. Aarti Drugs has TTM P/E ratio 22.43 as compared to the sector P/E of 23.40.There are 1 analysts who have initiated coverage on Aarti Drugs. There are 0.00 analysts who have given it a strong buy rating & 0.00 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 40.54 Crores in its last quarter.Listed peers of Aarti Drugs include Torrent Pharmaceuticals (-1.04%), Divi's Laboratories (-1.78%), Sun Pharmaceutical Industries (-0.43%).The Mutual Fund holding in Aarti Drugs was at 10.03% in 31 Dec 2025. The MF holding has decreased from the last quarter. The FII holding in Aarti Drugs was at 2.15% in 31 Dec 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Feb 07, 2026, 02:33 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.71
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.45
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.27
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    2.50
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    17.28
    Lower than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -2.85
    Indicates undervaluation
Price range
Day Range
Lowest
371.20
Highest
377.85
52 week range
Lowest
312.50
Highest
574.95
Aarti Drugs News
Aarti Drugs Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Torrent Pharmaceuticals
Neutral
3,931.65-1.041,33,059.5567.3217.10.8317.62
Divi's Laboratories
Bearish
6,027.00-1.781,60,509.2878.6111.520.460.01
Sun Pharmaceutical Industries
Neutral
1,694.90-0.434,06,653.7036.245.770.920.50
Cipla
Moderately Bearish
1,330.80-0.141,07,490.2122.953.870.870.81
Dr Reddy's Laboratories
Neutral
1,241.60-0.291,03,622.8618.633.140.632.34
Mutual Fund Ownership
View all
DSP Small Cap Fund Regular Plan Growth
3/5
  • Amount Invested (Cr.) 282.29
  • % of AUM 1.73
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
NA
  • Amount Invested (Cr.) 70.57
  • % of AUM 1.28
DSP Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 37.83
  • % of AUM 1.28
DSP Value Fund Regular Plan Growth
3/5
  • Amount Invested (Cr.) 3.13
  • % of AUM 0.31
Motilal Oswal Nifty Microcap 250 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 4.84
  • % of AUM 0.20
Aarti Drugs Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-02-03Quarterly Results & Interim Dividend
2025-11-07Quarterly Results
2025-07-18Quarterly Results
2025-05-06Audited Results
2025-01-29Quarterly Results & Interim Dividend
About the company Aarti Drugs
  • IndustryBiotechnology & Drugs
  • ISININE767A01016
  • BSE Code524348
  • NSE CodeAARTIDRUGS
Aarti Drugs Limited is an India-based company, which is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates in the pharmaceuticals segment. Its geographical segments include Out of India and India. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals include benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.
  • Management Info
  • Prakash PatilChairman of the Board, Chief Executive Officer, Managing Director, Executive Director
  • Adhish PatilChief Financial Officer, Chief Operating Officer
  • Rushikesh DeoleCompliance Officer, Company Secretary
  • Harshit SavlaJoint Managing Director, Executive Director
  • Rashesh GogriManaging Director, Executive Director
  • Uday PatilExecutive Director
  • Harit Pragji ShahExecutive Director
Aarti Drugs Share Price FAQs

Aarti Drugs is trading at 375.20 as on Fri Feb 06 2026 10:10:57. This is 0.27% upper as compared to its previous closing price of 374.20.

The market capitalization of Aarti Drugs is 3417.14 Cr as on Fri Feb 06 2026 10:10:57.

The average broker rating on Aarti Drugs is Hold. The breakup of analyst rating is given below -

  • 0.00 analysts have given a strong buy rating
  • 0.00 analysts have given a buy rating
  • 1 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Aarti Drugs is 574.95 whereas the 52 wk low is 312.50

Aarti Drugs can be analyzed on the following key metrics -

  • TTM P/E: 22.43
  • Sector P/E: 23.40
  • Dividend Yield: 0.27%
  • D/E ratio: 0.39

Aarti Drugs reported a net profit of 168.16 Cr in 2025.

The Mutual Fund Shareholding was 10.03% at the end of 31 Dec 2025.

Quick Links
EQUITY QUICK LINKS
Aarti Drugs QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Aarti Drugs share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.